Lakefront Biotherapeutics (LKFT) Profit After Tax (2014 - 2026)

Lakefront Biotherapeutics (LKFT) has reported Profit After Tax for 13 consecutive years, with $15.8 million the latest figure, recorded in Q1 2026.

• Quarterly Profit After Tax rose 108.98% year-over-year to $15.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $556.8 million (up 570.62% YoY) and the FY2025 annual result came in at $365.2 million, up 333.15% from the prior year.
• Profit After Tax fell to $15.8 million in Q1 2026 per LKFT's latest filing, from $890.0 million in the prior quarter.
• Over the last five years, Profit After Tax for LKFT reached as high as $890.0 million in Q4 2025 and fell as low as -$524.7 million in Q3 2025.
• A 5-year average of $26.9 million and a median of $15.8 million in 2026 frame the typical range for Profit After Tax.
• The largest YoY upside for Profit After Tax was 2990.63% in 2025 against a maximum downside of 1970.93% in 2025.
• Year by year, Profit After Tax stood at -$235.8 million in 2022, then soared by 184.69% to $199.7 million in 2023, then plunged by 85.58% to $28.8 million in 2024, then soared by 2990.63% to $890.0 million in 2025, then slumped by 98.22% to $15.8 million in 2026.
• According to Business Quant data, Profit After Tax over the past three periods registered $15.8 million, $890.0 million, and -$524.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.